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Abstract
Idiopathic pulmonary fibrosis (IPF) is a common form of interstitial lung disease and usually results in
progressive respiratory insufficiency and death. Steady progress has been made in understanding the
pathogenesis of IPF and multiple clinical trials are ongoing, but effective therapy remains elusive.
Introduction and context
Idiopathic pulmonary fibrosis (IPF) is the most common
form of interstitial lung disease and occurs predomi-
nantly in middle-aged and older adults. It is defined by
the histopathologic pattern of usual interstitial pneumo-
nia occurring in the absence of an identifiable cause of
lung injury such as drug toxicity, inhalational agents,
connective tissue disease, and so on [1-3]. Median
survival time following diagnosis of IPF is 2-3 years
[2-5]. Although consensus has been achieved in the
definition of this disorder and advances have occurred in
our understanding of the mechanisms of lung fibrosis,
effective therapy has remained elusive.
The cause of IPF remains unknown. Developing knowl-
edge of the pathogenesis of IPF has shifted focus towards
the role of epithelial injury, dysregulated wound healing,
and fibrosis and away from inflammation as the
predominant pathologic process [6,7]. Thus, the search
for effective therapeutic agents for the treatment of IPF
has also shifted to agents with antifibrotic properties and
away from anti-inflammatory treatments [8]. In addi-
tion, there is growing interest in vasomodulators to treat
pulmonary hypertension, which commonly occurs in
patients with IPF, as well as pulmonary rehabilitation to
improve the quality of life of these patients [9,10].
Recent advances
Pharmacologic agents
Traditional therapy for IPF has used glucocorticoids in
conjunction with azathioprine or cyclophosphamide
with the aim of reducing inflammation in the lung
parenchyma as dictated by the previous paradigm [5].
This approach is associated with drug-related adverse
effects and efficacy has never been validated.
Gamma-interferon
Gamma-interferoncausedexcitementasatreatmentforIPF
when Ziesche and colleagues [11] reported dramatic
improvement in an open, randomized trial of 18 IPF
patients. This initial enthusiasm was tempered when a
randomized,double-blind,placebo-controlledclinicaltrial
of 330 IPF patients showed no difference between placebo
and gamma-interferon groups in progression-free survival,
pulmonary function, or quality of life outcome measures
[12]. A third study evaluated the role of gamma-interferon
therapy in selected IPF patients with mild-to-moderate
physiological impairment (‘early disease’)a n da l s of a i l e d
to show improved survival [13]. Gamma-interferon
therapy is not recommended in the treatment of IPF.
N-Acetylcysteine
N-Acetylcysteine (NAC) is an antioxidant available in an
oral form with or without a prescription. In a study of IPF
patients treated with prednisone and azathioprine the
addition of NAC compared to placebo was associated
with a slower deterioration in forced vital capacity
and single breath carbon monoxide diffusing capacity
at 12 months [14]. However, the measured functional
benefit was rather modest. In addition, the absence of
placebo control in this study makes interpretation of
these results uncertain.
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A tumor necrosis factor-alpha antagonist, etanercept
(a recombinant soluble human tumor necrosis factor
receptor), was investigated in a clinical trial exploring its
possible role in the treatment of IPF. Etanercept therapy
was well tolerated but no differences were noted in the
primary endpoints, including changes from baseline in
forcedvitalcapacity(percentpredicted),diffusingcapacity
for carbon monoxide (percent predicted), and alveolar-
arterial oxygen gradient at 48 weeks [15].
Pirfenidone
Pirfenidone is a pyridone compound with broad
antifibrotic properties. In a double-blind, randomized,
placebo-controlled trial involving 107 subjects, no
significant difference was seen in the primary endpoint
of the change in the lowest oxygen saturation by pulse
oximetry during a 6-minute exercise test between base-
line and 9 months [16]. However, pirfenidone therapy
was associated with a smaller decline in vital capacity
and reduced incidence of acute exacerbations. In a
subsequent trial (275 subjects) that employed change
in vital capacity as the primary endpoint, pirfenidone
therapy was associated with a decreased rate of decline in
vital capacity and increased progression-free survival
time (a secondary endpoint). A manuscript describing
the results of this study has been published online [17].
Pirfenidone is currentlyunder reviewby the US Food and
Drug Administration for use in the treatment of IPF.
Imatinib
Imatinib is a tyrosine kinase inhibitor that has been
shown to inhibit lung fibrosis in bleomycin models
of pulmonary fibrosis. A randomized clinical trial of
119 patients with mild-to-moderate IPF failed to show a
favorable effect on survival or lung function [18]. There
was a significant dropout rate in this study, which may
have been underpowered. It remains unclear whether
other tyrosine kinase inhibitors may have a role in the
treatment of IPF.
Anticoagulant therapy
In 2005, Kubo and colleagues reported prednisolone
plus anticoagulant therapy was associated with a marked
reduction in mortality in patients with acute exacerba-
tion of IPF compared to those on prednisolone alone.
However, this was an unblinded study that included a
relatively modest number of patients (56 subjects)
and had a 26% dropout rate in the anticoagulant arm
of the study. It is possible that anticoagulant therapy may
have a role in the treatment of IPF since parenchymal
injury in IPF may be associated with pulmonary vascular
microthrombi and IPF patients are at risk for venous
thromboembolism. Therefore, a multicenter clinical trial
investigating the use of anticoagulant therapy has been
initiated within the National Institutes of Health (NIH)-
sponsored IPF Clinical Research Network. At the present
time, we do not recommend the use of anticoagulant
therapy in the treatment of IPF.
Vasomodulatory agents
Pulmonary hypertension is a relatively common compli-
cation of IPF and adversely affects prognosis [9,20-23].
Increasing numbers of vasomodulatory agents have
becomeavailableinrecentyearsandsomeoftheseagents
have been studied in IPF patients with pulmonary
hypertension [24]. In a double-blind, randomized
clinical trial, bosentan therapy failed to show superiority
over placebo on 6-minute walk distance but did
demonstrate a trend toward delayed time of death or
disease progression, and improvement in quality of life
measures. Results of another bosentan study, BUILD-3
(BosentanUseinInterstitialLungDisease3),arepending.
In an open-label study of 14 IPF patients, sildenafil
therapy improved 6-minute walk distance and was well-
tolerated [25]. A multicenter clinical trial on the effects
of sildenafil therapy was recently completed in the
NIH-sponsored IPF Clinical Research Network and the
results are pending. Based on the data available to date,
bosentan and sildenafil are not recommended in the
treatment of IPF patients with pulmonary hypertension.
Other management modalities
Although there are no high-quality data demonstrating
the benefit of supplemental oxygen therapy for patients
with IPF, it is prudent to provide supplemental oxygen
therapy for those with resting hypoxemia or significant
oxygen desaturation with exercise on room air. In such
patients supplemental oxygen therapy likely provides
benefit in symptoms and quality of life. Other suppor-
tive measures to be addressed include optimization of
the nutritional status and updating of immunizations.
Deconditioning is a common problem for IPF patients,
particularly those with advanced disease, and can
exacerbate functional and psychosocial impairments.
Pulmonary rehabilitation can improve symptoms, walk
distance, and quality of life [10].
The role of gastroesophageal reflux and acid aspiration in
the pathogenesis of IPF remains unsettled [26]. It is
reasonable to treat IPF patients who have symptomatic
gastroesophageal reflux with acid-suppressive medica-
tions and anti-reflux measures. Fundoplication may be
indicated in IPF patients with persistent gastroesopha-
geal reflux symptoms or esophagitis who fail
medical therapy or in those likely to undergo lung
transplantation.
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survival rate of 40-50% [27,28]. Appropriate patients
with IPF should be offered an opportunity for
lung transplant evaluation without undue delay since
those with IPF have excess mortality compared to
patients with other lung diseases awaiting lung
transplantation.
Implications for clinical practice
In the absence of strong evidence favoring the use of any
pharmacologic agent in the treatment of IPF, clinicians
and patients need to reach an informed decision
regarding possible management options. None of the
currently available pharmacologic agents is supported
by enough evidence to warrant their routine clinical use.
In those patients who wish to undergo a trial of
pharmacologic therapy, options include NAC mono-
therapy and NAC combined with prednisone and
azathioprine. Pirfenidone may also prove to be a
reasonable option, if it becomes available. Whenever
possible, patients with IPF should be offered participa-
tion in ongoing clinical trials in order to identify
effective treatments for IPF. Those patients who are
appropriate candidates for lung transplantation
should be referred promptly for an evaluation since
the clinical course of IPF can be unpredictable, (e.g.,
acute exacerbation).
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